These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 25427155)

  • 1. Plasma microRNAs as potential noninvasive biomarkers for in-stent restenosis.
    He M; Gong Y; Shi J; Pan Z; Zou H; Sun D; Tu X; Tan X; Li J; Li W; Liu B; Xue J; Sheng L; Xiu C; Yang N; Xue H; Ding X; Yu C; Li Y
    PLoS One; 2014; 9(11):e112043. PubMed ID: 25427155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differentially expressed miR-152, a potential biomarker for in-stent restenosis (ISR) in peripheral blood mononuclear cells (PBMCs) of coronary artery disease (CAD) patients.
    Maheronnaghsh M; Niktab I; Enayati S; Amoli MM; Hosseini SK; Tavakkoly-Bazzaz J
    Nutr Metab Cardiovasc Dis; 2021 Apr; 31(4):1137-1147. PubMed ID: 33712363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating level of microRNA-142-5p is a potential biomarker for predicting in-stent restenosis: a case-control study.
    Pan CH; Chien SC; Chen CJ; Shih CM; Hsieh MH; Huang CY; Bi WF; Chan CS; Kao YT; Hsiao CY; Chiang SJ; Chiang KH; Huang JH; Liu YR; Luo JD; Huang HY; Wu CH
    BMC Cardiovasc Disord; 2021 Feb; 21(1):77. PubMed ID: 33557763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Active matrix metalloproteinases 3 and 9 are independently associated with coronary artery in-stent restenosis.
    Jones GT; Tarr GP; Phillips LV; Wilkins GT; van Rij AM; Williams MJ
    Atherosclerosis; 2009 Dec; 207(2):603-7. PubMed ID: 19576586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating miRNA-23b and miRNA-143 Are Potential Biomarkers for In-Stent Restenosis.
    Saavedra N; Rojas G; Herrera J; Rebolledo C; Ruedlinger J; Bustos L; Bobadilla B; Pérez L; Saavedra K; Zambrano T; Lanas F; Salazar LA
    Biomed Res Int; 2020; 2020():2509039. PubMed ID: 33015157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of insulin resistance on in-stent restenosis in patients undergoing coronary drug-eluting stent implantation after long-term angiographic follow-up.
    Zhao LP; Xu WT; Wang L; Li H; Shao CL; Gu HB; Chan SP; Xu HF; Yang XJ
    Coron Artery Dis; 2015 Jan; 26(1):5-10. PubMed ID: 25211654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of post-intervention minimal stent area on 9-month follow-up patency of paclitaxel-eluting stents: an integrated intravascular ultrasound analysis from the TAXUS IV, V, and VI and TAXUS ATLAS Workhorse, Long Lesion, and Direct Stent Trials.
    Doi H; Maehara A; Mintz GS; Yu A; Wang H; Mandinov L; Popma JJ; Ellis SG; Grube E; Dawkins KD; Weissman NJ; Turco MA; Ormiston JA; Stone GW
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1269-75. PubMed ID: 20129555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors for functionally significant in-stent restenosis: an integrated analysis using coronary angiography, IVUS, and myocardial perfusion imaging.
    Kang SJ; Cho YR; Park GM; Ahn JM; Han SB; Lee JY; Kim WJ; Park DW; Lee SW; Kim YH; Lee CW; Park SW; Mintz GS; Park SJ
    JACC Cardiovasc Imaging; 2013 Nov; 6(11):1183-90. PubMed ID: 24229771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized comparison of drug-eluting balloon versus everolimus-eluting stent in patients with bare-metal stent-in-stent restenosis: the RIBS V Clinical Trial (Restenosis Intra-stent of Bare Metal Stents: paclitaxel-eluting balloon vs. everolimus-eluting stent).
    Alfonso F; Pérez-Vizcayno MJ; Cárdenas A; García Del Blanco B; Seidelberger B; Iñiguez A; Gómez-Recio M; Masotti M; Velázquez MT; Sanchís J; García-Touchard A; Zueco J; Bethencourt A; Melgares R; Cequier A; Dominguez A; Mainar V; López-Mínguez JR; Moreu J; Martí V; Moreno R; Jiménez-Quevedo P; Gonzalo N; Fernández C; Macaya C;
    J Am Coll Cardiol; 2014 Apr; 63(14):1378-86. PubMed ID: 24412457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of drug-eluting stents in-stent restenosis with paclitaxel-coated balloon angioplasty: Insights from the French "real-world" prospective GARO Registry.
    Auffret V; Berland J; Barragan P; Waliszewski M; Bonello L; Delarche N; Furber A; Albert F; Carrié D; Eltchaninoff H; Pansieri M; Schneeberger M; Piot C; Marcollet P; Bedossa M
    Int J Cardiol; 2016 Jan; 203():690-6. PubMed ID: 26583844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Late Restenosis After Paclitaxel-Coated Balloon Angioplasty Occurs in Patients With Drug-Eluting Stent Restenosis.
    Habara S; Kadota K; Shimada T; Ohya M; Amano H; Izawa Y; Kubo S; Hyodo Y; Otsuru S; Hasegawa D; Tada T; Tanaka H; Fuku Y; Goto T; Mitsudo K
    J Am Coll Cardiol; 2015 Jul; 66(1):14-22. PubMed ID: 26139053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The value of serum visfatin in predicting in-stent restenosis of drug-eluting stents.
    Wu XA; Xie G; Li XQ; Wu HT; Wang X
    Clin Chim Acta; 2018 Apr; 479():20-24. PubMed ID: 29305846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and pathological characteristics of homogeneous and nonhomogeneous tissue of in-stent restenosis visualized by optical coherence tomography.
    Itoh T; Fusazaki T; Kimura T; Oikawa H; Sasou S; Ishikawa Y; Goto I; Komuro K; Nakajima S; Koeda Y; Kaneko K; Nishiyama O; Nakamura M; Morino Y
    Coron Artery Dis; 2015 May; 26(3):201-11. PubMed ID: 25714072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of plasma aldosterone levels for prediction of in-stent restenosis.
    Amano T; Matsubara T; Izawa H; Torigoe M; Yoshida T; Hamaguchi Y; Ishii H; Miura M; Hayashi Y; Ogawa Y; Murohara T
    Am J Cardiol; 2006 Mar; 97(6):785-8. PubMed ID: 16516576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of red blood cell distribution in predicting drug-eluting stent restenosis in patients with stable angina pectoris after coronary stenting.
    Zhao K; Li YJ; Gao S
    Coron Artery Dis; 2015 May; 26(3):220-4. PubMed ID: 25647458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of drug-eluting stents for treating in-stent restenosis of drug-eluting stents (from the Korean DES ISR multicenter registry study [KISS]).
    Ko YG; Kim JS; Kim BK; Choi D; Hong MK; Jeon DW; Yang JY; Ahn YK; Jeong MH; Yu CW; Yun KH; Lim DS; Jang Y;
    Am J Cardiol; 2012 Mar; 109(5):607-13. PubMed ID: 22172241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicenter randomized comparison of paclitaxel-coated balloon catheter with conventional balloon angioplasty in patients with bare-metal stent restenosis and drug-eluting stent restenosis.
    Habara S; Iwabuchi M; Inoue N; Nakamura S; Asano R; Nanto S; Hayashi Y; Shiode N; Saito S; Ikari Y; Kimura T; Hosokawa J; Nakamura M; Kotani J; Kozuma K; Mitsudo K
    Am Heart J; 2013 Sep; 166(3):527-33. PubMed ID: 24016503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcomes after the percutaneous treatment of drug-eluting stent restenosis.
    Latib A; Mussardo M; Ielasi A; Tarsia G; Godino C; Al-Lamee R; Chieffo A; Airoldi F; Carlino M; Montorfano M; Colombo A
    JACC Cardiovasc Interv; 2011 Feb; 4(2):155-64. PubMed ID: 21349453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating microRNA-21 as Stable Blood-Based Markers for Patients With ISR After PCI.
    Zhang X; Xiao XP; Ren XA; Xue W
    Heart Surg Forum; 2020 Oct; 23(6):E756-E762. PubMed ID: 33234202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significant association of coronary stent fracture with in-stent restenosis in sirolimus-eluting stents.
    Kim JS; Lee SY; Lee JM; Yoon YW; Ahn CM; Kim MH; Min PK; Ko YG; Hong BK; Choi D; Kwon HM; Jang Y; Shim WH
    Coron Artery Dis; 2009 Jan; 20(1):59-63. PubMed ID: 19008765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.